KDR and neoplasm: The FDA approved cabozantinib, also known as cabometyx, as a small-molecule dual-targeting inhibitor of the tyrosine kinases c-Met (mesenchymal-epithelial transition factor) and VEGFR-2 (Vascular Endothelial Growth Factor Receptor), demonstrating its ability to inhibit tumor growth, metastasis, and angiogenesis (Abou-Alfa et al., 2018).